Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
March 18, 2024 16:05 ET
|
Adverum Biotechnologies, Inc.
- Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity and an encouraging safety profile in patients with wet AMD - -...
Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference
February 28, 2024 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly...
Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 12, 2024 08:00 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
February 08, 2024 07:00 ET
|
Adverum Biotechnologies, Inc.
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and...
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing
February 05, 2024 07:45 ET
|
Adverum Biotechnologies, Inc.
- Financing led by TCGX with participation from new and existing investors including 5AM Ventures, Commodore Capital, Frazier Life Sciences, Logos Capital, Samsara BioCapital, Venrock Healthcare...
Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024
February 01, 2024 17:30 ET
|
Adverum Biotechnologies, Inc.
- Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD will be presented at the 47th Annual Meeting of the Macula Society, with...
Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer
January 29, 2024 08:00 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society
December 07, 2023 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference
November 28, 2023 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights
November 09, 2023 16:05 ET
|
Adverum Biotechnologies, Inc.
- Announced preliminary aflibercept protein levels from the on-going Phase 2 LUNA trial, suggesting that both doses are within the therapeutically active range and consistent with aflibercept levels...